Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Study of Myopia Prevention in Children With Low Concentration of Atropine

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified October 2007 by Min-Sheng General Hospital.
Recruitment status was:  Recruiting
Information provided by:
Min-Sheng General Hospital Identifier:
First received: October 6, 2007
Last updated: October 9, 2007
Last verified: October 2007
The purpose of this study is to test the hypothesis that myopia can be prevented by using a low concentration of atropine eyedrops once a week.

Condition Intervention Phase
Drug: atropine
Drug: tropicamide
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single Blind (Outcomes Assessor)
Primary Purpose: Prevention
Official Title: Pilot Study of Prevention Myopia in Children With Low Concentration of Atropine

Resource links provided by NLM:

Further study details as provided by Min-Sheng General Hospital:

Primary Outcome Measures:
  • cycloplegic refraction, visual acuity [ Time Frame: one year ]

Secondary Outcome Measures:
  • axial length [ Time Frame: one year ]

Estimated Enrollment: 60
Study Start Date: April 2007
Estimated Study Completion Date: March 2008
Arms Assigned Interventions
Experimental: 1
use 0.25% atropine once a week
Drug: atropine
0.25% atropine
Active Comparator: 2
use 0.5% tropicamide everyday
Drug: tropicamide
0.5% tropicamide

Detailed Description:

The prevalence rate of myopia is rising rapidly in several Asian countries. A prevalence survey conducted in 1995 of 11178 school children in Taiwan were 12 percent for six year old and 84 percent for teenagers 16 o 18 years. Among them, twenty percent were high myopes. While in the United States and Europe the prevalence rate in older adults is 20% to 50%. The rate of progression of myopia is highest in young children, and the average age of stabilization of myopia is approximately 16 years.The onset of myopia may occur at a relatively young age, leading to higher risks of high myopia (myopia at least 6.0 diopters ) in adulthood. High myopia is associated with potentially blinding complications. Therefore, prevention of myopia progression is important in Taiwan, especially in young children.

There is some evidence that atropine eyedrops retard myopia progression in three randomized clinical trials. It is believed that atropine act on muscarinic receptor located in the sclera and through some unknown mechanism retard the elongation rate of axial length. However, the possible long-term side effects such as cataract formation and retinal toxicity, are largely unknown. Photophobia in daily life, accommodation difficulty both decrease the acceptance of atropine usage and compliance.

There are some evidence that the rate of axial elongation of eyeball are different between pre-myopic stage and myopic stage. Therefore, if we can use low concentration of atropine eyedrops before myopia development. Maybe we can prevent abnormal axial length elongation with lower dosage of atropine eyedrops compared with daily use of atropine eyedrops in true myopia stage.

Clinical study was conducted by randomized control trial. 60 school-aged children were recruited ( Age 7 to 12 years ). All with pre-myopia ( spherical equivalent between +0.50 and -0.75 ) after cycloplegic refraction. Visual acuity of naked eyes are above 0.6. None of them had tropia, amblyopia, eyelid disease, ocular problems. The astigmatism was less than -1.0D and anisometropia was less than 1.0D. The children were randomly assigned into two groups by using randomized consent design. The first group use 0.25% atropine once a week. The second group keep traditional treatment using 0.5% tropicamide eyedrop every day. All children had complete ophthalmologic examination before enrollment. Follow-up examinations were performed every 3 months for 12 months duration. These examinations included visual acuity of naked eye. Intraocular pressure, refractive status. The cycloplegic refraction and axial length were measured every 6 months.


Ages Eligible for Study:   7 Years to 12 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Aged 7 to 12 years old
  • Has pre-myopia (spherical equivalent between +0.50 and -0.75) after cycloplegic refraction.
  • Visual acuity of naked eyes are above 0.6.
  • Astigmatism is less than -1.0D and anisometropia less than 1.0D.

Exclusion Criteria:

  • Has tropia, amblyopia, eyelid disease, or ocular problems.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00541177

Contact: Leon Chih-Kai Liang, MD MMS 03-3179599 ext 8333

Min-Sheng General Hospital Recruiting
Tao-Yuan, Taiwan
Sponsors and Collaborators
Min-Sheng General Hospital
Principal Investigator: Leon Chih-Kai Liang, MD MMS Min-Sheng General Hospital; National Yang-Ming university, Taiwan
  More Information Identifier: NCT00541177     History of Changes
Other Study ID Numbers: IRB960209-3
Study First Received: October 6, 2007
Last Updated: October 9, 2007

Keywords provided by Min-Sheng General Hospital:
prevention myopia

Additional relevant MeSH terms:
Refractive Errors
Eye Diseases
Adjuvants, Anesthesia
Anti-Arrhythmia Agents
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Asthmatic Agents
Respiratory System Agents
Muscarinic Antagonists
Cholinergic Antagonists
Cholinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action processed this record on April 28, 2017